MEI Pharma Reports Fiscal Year End 2024 Cash Position
Confirms Continuation of Evaluation of Strategic Alternatives
Previously on
To best preserve the Company’s existing cash, the Company commenced a reduction-in-force on
There can be no assurance the exploration of strategic alternatives will result in any agreements or transactions, or, if completed, any agreements or transactions will be successful or on attractive terms. The Company does not expect to disclose developments with respect to this process unless or until the evaluation of strategic alternatives has been completed or the Board of Directors has concluded disclosure is appropriate or legally required.
As of
About
Forward-Looking Statements
Certain information contained in this press release that are not historical in nature are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 including, without limitation, statements regarding the Company’s ability to identify, assess and execute a strategic transaction or realize value from its existing assets, the Company’s ability to preserve cash in order to adequately fund an orderly wind down of its operations if no transaction is consummated, the ability of stockholders and other stakeholders to realize any value or recovery as part of a transaction or a wind down process, the Company’s workforce reduction and future charges expected to be incurred in connection therewith, the adequacy or sufficiency of the Company’s existing cash resources and other statements. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management’s current expectations and are subject to a number of risks and uncertainties, including, but not limited to the Company’s ability to identify attractive strategic alternatives; the Company’s ability to retain key personnel; the adequacy of the Company’s capital resources in light of changing circumstances; the actions of various stakeholders of the Company; uncertainty regarding the impact of rising inflation and the increase in interest rates as a result; potential economic downturn; activist investors; government regulation; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.
| CONSOLIDATED BALANCE SHEETS | |||||||
| (In thousands, except par value amounts) | |||||||
|
|
|||||||
|
|
2024 |
|
|
|
2023 |
|
|
|
ASSETS |
|||||||
| Current assets: | |||||||
| Cash and cash equivalents |
$ |
3,705 |
|
$ |
16,906 |
|
|
| Short-term investments |
|
34,640 |
|
|
83,787 |
|
|
| Unbilled receivables |
|
- |
|
|
85 |
|
|
| Prepaid expenses and other current assets |
|
2,424 |
|
|
6,750 |
|
|
| Total current assets |
|
40,769 |
|
|
107,528 |
|
|
| Operating lease right-of-use asset |
|
214 |
|
|
11,972 |
|
|
| Property and equipment, net |
|
392 |
|
|
1,309 |
|
|
| Total assets |
$ |
41,375 |
|
$ |
120,809 |
|
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY |
|||||||
| Current liabilities: | |||||||
| Accounts payable |
$ |
3,168 |
|
$ |
6,134 |
|
|
| Accrued liabilities |
|
5,187 |
|
|
12,461 |
|
|
| Deferred revenue |
|
- |
|
|
317 |
|
|
| Operating lease liability |
|
- |
|
|
1,428 |
|
|
| Total current liabilities |
|
8,355 |
|
|
20,340 |
|
|
| Deferred revenue, long-term |
|
- |
|
|
64,545 |
|
|
| Operating lease liability, long-term |
|
- |
|
|
11,300 |
|
|
| Total liabilities |
|
8,355 |
|
|
96,185 |
|
|
| Stockholders' equity: | |||||||
| Preferred stock, |
|||||||
| none outstanding |
|
- |
|
|
- |
||
| Common stock, |
|||||||
| authorized; 6,663 shares issued and outstanding | |||||||
| at |
|
- |
|
|
- |
|
|
| Additional paid-in-capital |
|
421,239 |
|
|
430,621 |
|
|
| Accumulated deficit |
|
(388,219 |
) |
|
(405,997 |
) |
|
| Total stockholders' equity |
|
33,020 |
|
|
24,624 |
|
|
| Total liabilities and stockholders' equity |
$ |
41,375 |
|
$ |
120,809 |
|
|
| CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||
| (In thousands, except per share amounts) | ||||||||
|
Years Ended |
||||||||
|
|
2024 |
|
|
|
2023 |
|
||
| Revenues |
$ |
65,297 |
|
$ |
48,816 |
|
||
| Operating expenses: | ||||||||
| Research and development |
|
16,561 |
|
|
52,450 |
|
||
| General and administrative |
|
23,295 |
|
|
33,130 |
|
||
| Impairment of long-lived assets |
|
10,899 |
|
|
- |
|
||
| Total operating expenses |
|
50,755 |
|
|
85,580 |
|
||
| Income (loss) from operations |
|
14,542 |
|
|
(36,764 |
) |
||
| Other income (expense): | ||||||||
| Change in fair value of warrant liability |
|
- |
|
|
1,603 |
|
||
| Interest and dividend income |
|
3,277 |
|
|
3,345 |
|
||
| Other expense, net |
|
(41 |
) |
|
(22 |
) |
||
| Net income (loss) |
$ |
17,778 |
|
$ |
(31,838 |
) |
||
| Net income (loss) per share - basic and diluted |
$ |
2.67 |
|
$ |
(4.78 |
) |
||
| Weighted-average shares used in computing | ||||||||
| net income (loss) per share - basic and diluted |
|
6,663 |
|
|
6,663 |
|
||
View source version on businesswire.com: https://www.businesswire.com/news/home/20240919436864/en/
858-898-0976
investor@meipharma.com
Source: